Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Abstract
Immunotherapy has dramatically changed the cancer treatment landscape during the past decade, but very limited efficacy has been reported against pancreatic cancer. Several factors unique to pancreatic cancer may explain the resistance: the well-recognized suppressive elements in the tumor microenvironment, the functional and structural barrier imposed by the stroma components, T-cell exhaustion, the choice of perhaps the wrong immune targets, and microbial factors including gut dysbiosis and the unexpected presence of tumor microbes. Furthermore, we discuss various strategies to overcome these barriers.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-18-0900
Entities
People
- Florencia Mcallister
- Pawel K Mazur
- Robert Harrison Hester
Organizations
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
- National Institutes of Health
- Neuroendocrine Tumor Research Foundation
- United States Department of Defense
- University of Texas at Austin